The Value of Genetic and Genomic Technologies Workshop Summary (2010) / Chapter Skim
Currently Skimming:
Appendix D: Warfarin Topic Brief
Appendix D: Warfarin Topic Brief
Pages 77-82
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 77... ...
used to monitor anticoagulation response and monitoring and dose adjustment occurring every 2–6 weeks. The use of genomic information may improve the ability to predict an optimal initial dose, thus improving therapeutic response during warfarin initiation, when the risk of overanticoagulation and major bleeding events is highest.
|
From page 78... ...
. Recommendations by Payers CMS recently issued a coverage decision for warfarin pharmacogenomic testing that specifies testing will be reimbursed only for patients initiating warfarin who are enrolled in a randomized controlled trial that measures major bleeding and thromboembolic events.
|
From page 79... ...
. The trial will enroll approximately 1,200 patients, measure the percentage of time in therapeutic range over the first month as the primary outcome, and compare clinical versus clinical plus genomic algorithms for dose initiation.
|
From page 80... ...
. Several more recent studies have come to the conclusion that warfarin pharmacogenomic testing is unlikely to be cost effective unless testing costs drop significantly and the uncertainty around effectiveness is reduced (Eckman et al., 2009; Meckley et al., 2010; Patrick et al., 2009)
|
From page 81... ...
2006. Health care savings from personalizing medicine using genetic testing: The case of warfarin.
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.